SCHEMBL20938570

SCHEMBL20938570

CNC(=O)NC(=O)Nc1ccccccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.64
TP53 P04637 1/20 0.64
EPHX1 P07099 1/20 0.64
TSHR P16473 1/20 0.64
EPHX2 P34913 1/20 0.64
CDK9 P50750 1/20 0.64
CLK4 Q9HAZ1 1/20 0.64
NPC1 O15118 3/20 0.60
RAB9A P51151 3/20 0.60
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
TAAR1 Q96RJ0 3/20 0.57
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
HSD17B10 Q99714 2/20 0.54
NAPRT Q6XQN6 1/20 0.54
MAOA P21397 2/20 0.53
MAOB P27338 2/20 0.53
MAPT P10636 1/20 0.53
ALDH1A1 P00352 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714237 0.89 SMN1; SMN2 (0.73) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL10401175 0.89 SMN1; SMN2 (0.80) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL11238734 0.82 SMN1; SMN2 (0.57) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL23069076 0.82 NPC1 (0.65) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL9479624 0.82 CASP3 (0.77) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL2887905 0.81 NPC1 (0.70) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL8428905 0.80 SMN1; SMN2 (0.73) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL17589369 0.80 KMT2A (0.66) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL14029935 0.80 ALDH1A1 (0.81) SMN1; SMN2EPHX1TSHREPHX2NPC1
Hydrochloric Acid SCHEMBL11059549 0.80 SMN1; SMN2 (0.53) SMN1; SMN2TP53EPHX1TSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10946023-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2021-03-16 US disclosed
US-20190117661-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117661-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT SMN1; SMN2 568/4885TP53 2/4885EPHX1 1953/4885
US-10946023-B2 Therapeutically active compounds and their methods of use MCL1, TP53, BRDT SMN1; SMN2 568/4885TP53 2/4885EPHX1 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.